NASDAQ:ONVO Organovo (ONVO) Stock Forecast, Price & News $1.72 +0.02 (+1.18%) (As of 11:36 AM ET) Add Compare Share Share Today's Range$1.70▼$1.7450-Day Range$1.70▼$2.2752-Week Range$1.37▼$3.72Volume19,980 shsAverage Volume81,579 shsMarket Capitalization$14.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Organovo (NASDAQ:ONVO) StockOrganovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.Read More Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address ONVO Stock News HeadlinesMay 26, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)May 19, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.comJune 1, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.May 15, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) vs. PolarityTE (NASDAQ:PTE) Critical AnalysisMay 9, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Receives New Coverage from Analysts at StockNews.comApril 24, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.comApril 16, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Now Covered by StockNews.comApril 7, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comJune 1, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.March 21, 2023 | finance.yahoo.comOrganovo Announces FXR ProgramFebruary 10, 2023 | finance.yahoo.comWill Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?October 25, 2022 | finance.yahoo.comOrganovo Holdings, Inc. (ONVO)October 17, 2022 | finance.yahoo.comTrends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo FinanceOctober 12, 2022 | benzinga.comHuman Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - BenzingaOctober 9, 2022 | globenewswire.com3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswireOctober 3, 2022 | seekingalpha.comARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking AlphaSeptember 30, 2022 | prnewswire.comGlobal Laboratory Animal Models, 3D Cultures and Organoids Markets, 2019-2021 & 2022-2027 - Opportunities in Organoids in Drug Development, Personalized Medicine and Transplantational Medicine - PR NewswireSeptember 30, 2022 | businesswire.comGlobal Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business WireSeptember 29, 2022 | businesswire.com3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business WireSeptember 23, 2022 | benzinga.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket - American Vir - BenzingaSeptember 22, 2022 | uk.investing.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 16, 2022 | nasdaq.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - NasdaqSeptember 16, 2022 | uk.investing.comWhy Applied Optoelectronics Is Trading Higher By Around 31%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 14, 2022 | rttnews.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - RTTNewsSeptember 6, 2022 | globenewswire.comOrganovo to Participate in the H.C. Wainwright 24th Annual - GlobeNewswireSeptember 6, 2022 | globenewswire.comOrganovo Announces Postponement of Annual Meeting of Stockholders - GlobeNewswireSeptember 6, 2022 | finance.yahoo.comOrganovo Announces Postponement of Annual Meeting of StockholdersSee More Headlines ONVO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Company Calendar Last Earnings8/08/2019Today6/01/2023Next Earnings (Estimated)6/09/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,450,000.00 Net MarginsN/A Pretax Margin-685.54% Return on Equity-44.55% Return on Assets-40.10% Debt Debt-to-Equity RatioN/A Current Ratio15.71 Quick Ratio15.71 Sales & Book Value Annual Sales$1.50 million Price / Sales9.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book0.49Miscellaneous Outstanding Shares8,710,000Free Float8,366,000Market Cap$14.81 million OptionableOptionable Beta0.89 Key ExecutivesKeith MurphyExecutive Chairman & Chief Executive OfficerThomas P. HessChief Financial & Accounting OfficerJeffrey N. MinerChief Scientific OfficerCurtis TyreeSenior VP-Strategy & Business DevelopmentSteve E. KunszaboVP-Investor Relations & Corporate CommunicationsKey CompetitorsAcorda TherapeuticsNASDAQ:ACORPeak BioNASDAQ:PKBOEloxx PharmaceuticalsNASDAQ:ELOXFinch Therapeutics GroupNASDAQ:FNCHTRACON PharmaceuticalsNASDAQ:TCONView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 10,594 shares on 5/16/2023Ownership: 0.703%Renaissance Technologies LLCBought 19,430 shares on 5/12/2023Ownership: 1.509%View All Institutional Transactions ONVO Stock - Frequently Asked Questions How have ONVO shares performed in 2023? Organovo's stock was trading at $1.41 on January 1st, 2023. Since then, ONVO shares have increased by 20.6% and is now trading at $1.70. View the best growth stocks for 2023 here. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 9th 2023. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.77 million. When did Organovo's stock split? Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). What is Organovo's stock symbol? Organovo trades on the NASDAQ under the ticker symbol "ONVO." Who are Organovo's major shareholders? Organovo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.51%) and Susquehanna International Group LLP (0.70%). View institutional ownership trends. How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organovo's stock price today? One share of ONVO stock can currently be purchased for approximately $1.70. How much money does Organovo make? Organovo (NASDAQ:ONVO) has a market capitalization of $14.81 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How can I contact Organovo? Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com. This page (NASDAQ:ONVO) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.